# An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

> **NCT04155190** · PHASE2 · TERMINATED · sponsor: **Sol-Gel Technologies, Ltd.** · enrollment: 47 (actual)

## Conditions studied

- Recurrent Basal Cell Carcinoma

## Interventions

- **DRUG:** Patidegib Topical Gel, 2%
- **DRUG:** Patidegib Topical Gel, Vehicle

## Key facts

- **NCT ID:** NCT04155190
- **Lead sponsor:** Sol-Gel Technologies, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-20
- **Primary completion:** 2021-04-23
- **Final completion:** 2021-04-23
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Terminated early due to low blinded event rate
- **Last updated:** 2023-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04155190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04155190, "An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04155190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*